RICHMOND, Va.--(BUSINESS WIRE)--McKesson Medical-Surgical Inc., an affiliate of the McKesson Corporation, has signed an exclusive agreement with bioMérieux, Inc. to serve the U.S. community hospital market. The agreement highlights the two companies’ shared focus on antibiotic stewardship and preventing sepsis in hospital care settings by delivering better solutions for healthcare providers to fight infections and their often-deadly complications.
The following bioMérieux products and reagents will now be available through McKesson:
- VIDAS® B•R•A•H•M•S PCT™ run on VIDAS® 3 for guided antibiotic therapy in sepsis and lower respiratory-tract infections;
- BACT/ALERT® and FAN® Plus Media that optimizes time to detection and microorganism recovery
- VITEK® 2 for same day microbial identification and antibiotic susceptibility testing results
“This alliance enhances community hospital access to bioMérieux’s best-in-class diagnostic solutions. Tests like VIDAS® B•R•A•H•M•S PCT™, can empower hospitals to improve antimicrobial stewardship and positively impact patient care, no matter what their size,” said Brian Armstrong, Executive Vice President & General Manager, bioMérieux, Inc.
McKesson recognizes the strategic importance of laboratory services in the health care continuum, and has steadily accelerated its investment and growth in this segment over the past several years. This includes the 2016 acquisition of LABSCO, a national distributor of laboratory equipment and supplies, which expanded McKesson’s footprint in the segment.
McKesson values strong relationships with leading diagnostics manufacturers, like bioMérieux, as they enhance the value McKesson delivers to its many customers across the continuum of care. Through a robust portfolio of more products and more choices, McKesson can help its customers improve patient health and grow their business.
“We’re excited to partner with bioMérieux, Inc. and help represent its industry-leading in vitro diagnostics portfolio in the community hospital market,” said Doug Shaver, Senior Vice President and General Manager, McKesson Laboratory Solutions. “This reinforces McKesson’s commitment to bring a full suite of diagnostic solutions to community hospitals and support their efforts of effective antibiotic stewardship.”
For more than 50 years, bioMérieux has been a world leader in the field of in vitro diagnostics, present in more than 150 countries through 42 subsidiaries and a large network of distributors. The company provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
About McKesson Medical-Surgical
McKesson Medical-Surgical Inc. is an affiliate of the McKesson Corporation. McKesson Corporation, currently ranked 5th on the FORTUNE 500, is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. McKesson Medical-Surgical works with health systems, physician offices, extended care providers, in-home patients, labs, payers and others across the spectrum of care to build healthier organizations that deliver better care to patients in every setting. McKesson Medical-Surgical helps its customers improve their financial, operational, and clinical performance with solutions that include pharmaceutical and medical-surgical supply management, healthcare information technology, and business and clinical services. For more information, visit mms.mckesson.com.
